Adjuvant development within the context of a vaccine to protect against B. pertussis

预防百日咳博德特氏菌的疫苗佐剂开发

• 批准号: 10453427
• 负责人: LISA MORICI
• 金额: $ 197.72万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2023-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10453427
• 关键词: Adjuvant; Attenuated; Bordetella pertussis; Burkholderia; Development; Disease; Human; Immunologics; Investigation; Licensure; Lipid A; Membrane; Support Contracts; Testing; Vaccines; Vesicle; human disease; pathogen

This contract supports the development of an adjuvant through immunological characterization studies and compound optimization, up to and including IND-enabling studies. The main emphasis will be on testing and further development of the adjuvant for human licensure as a component of a licensed or investigational vaccine to protect against one or more non-HIV disease pathogens relevant to human disease.

该合同支持通过免疫学表征研究和化合物优化开发佐剂，包括IND使能研究。主要重点将是测试和进一步开发用于人类许可的佐剂，作为许可或研究疫苗的组成部分，以防止一种或多种与人类疾病相关的非HIV疾病病原体。